drugset / Trial / NCT06527755
A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers
NaSingle-groupOpen-labelOther
Summary
This is a Phase 1 study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of eplontersen following single dosing in healthy Chinese participants. The objectives of the study are: to characterize the pharmacokinetic (PK) profiles and the pharmacodynamic (PD) profiles, and to evaluate the safety and tolerability and the immunogenicity of eplontersen following subcutaneous administration of a single 45 mg dose in healthy Chinese participants.
Timeline
- Start
- 2024-08-06
- Primary completion
- 2024-09-11
- Completion
- 2024-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eplontersen | Antisense oligonucleotide | 45 mg | Subcutaneous |
Indications
No indication recorded.